Mark DeWitt is a Project Scientist at the University of California, Berkeley. After getting his PhD in Biophysics from Berkeley, he joined the IGI as a post-doc in Jacob Corn’s lab. Working with researchers at IGI and Children’s Hospital Oakland, Mark developed a method of efficient correction of the sickle mutation in CD34+ HSPCs. Mark is now managing a team of researchers at three UC institutions (Berkeley, UCSF, and UCLA) that are developing a clinical protocol using his post-doctoral work as a foundation. This work is funded by CIRM, and may enter trials as early as next year.